Brands

Performance Specifications

The assay uses 50 μL of sample and provides a broad detection range of 4.32 to 12,960 pg/mL* with an analytical sensitivity of ≤4.32 pg/mL.

Inter-Laboratory Correlation

10 human samples (T1DM, T2DM and Normal serum) were evaluated at three independent laboratories. The results from each of the laboratories were compared to results generated at ALPCO, demonstrating a high degree of correlation.

Comparison of Chemiluminescent and Colorimetric Assays with T1DM Samples

49 T1DM human serum samples were evaluated against a leading colorimetric assay. Of the 49 samples tested, 25 were detectable in the STELLUX® Assay and 15 were detectable in the colorimetric assay. This represents a >60% increase in sample detection when using the Human Chemi C-peptide ELISA.

C-peptide Profiles in Serum Samples

The Human Chemi C-peptide ELISA was used to elucidate the different profiles of C-peptide levels in Normal (Fasted and Fed), T1DM, and T2DM (Fasted and Fed) human samples. The profiles clearly differentiate normal individuals and individuals with diabetes.

Performance Specifications

The STELLUX® Chemi Human Insulin ELISA provides a broad detection range of 5- 30,000 pg/mL (0.14 - 862 μIU/mL) with an analytical sensitivity of 2 pg/mL and functional sensitivity of 20 pg/mL using only a 25 μL sample.

Precision & Correlation

Intra- and inter-assay precision values expressed less than 13.5% variation. Inter-laboratory testing demonstrated a high degree of correlation with an r2 value of 0.999.

Additionally, correlation between the ALPCO human insulin colorimetric ELISA assays and the STELLUX® human insulin chemiluminescent platform was evaluated. Results showed a high degree of correlation with r2 values of 0.97 and 0.95.

Performance Specifications

The assay provides a broad detection range of 5-3,000 pg/mL with an analytical sensitivity of <2.0 pg/mL and functional sensitivity of 5 pg/mL using only a 50 μL sample.

Specificity

The STELLUX® Human Intact Proinsulin ELISA demonstrates <1% cross reactivity with Des(31,32) proinsulin, ensuring only intact proinsulin is detected.

Inter-Laboratory Correlation

Internal Results

Performance Specifications

The assay provides a broad detection range of 5 - 3,000 pg/mL with an analytical sensivity of 0.455 pg/mL and functional sensitivity of 10 pg/mL using only a 50 μL sample.

Standard Curve

Specificity

The STELLUX® Human Total Proinsulin ELISA fully detects des(31,32) and des(64,65) proinsulin, ensuring all circulating forms of proinsulin are measured in a single assay.

Inter-Laboratory Correlation

Unparallelled Sensitivity

Performance Specifications

The assay provides a broad detection range of 0.1 – 150 ng/mL with an analytical sensitivity of 0.096 ng/mL and functional sensitivity of 0.15 ng/mL using only a 5 µL sample.

Standard Curve

Precision & Correlation

Intra- and inter-assay precision values expressed less than 13.5% variation. Inter-laboratory testing demonstrated a high degree of correlation with an r2 value of 0.999.

Data Analysis

The STELLUX® Plate Reader system is a compact, PC-controlled open chemiluminescent system designed to read and calculate the results of assays read in 96-well microtiter plates or strip trays. The reader’s built-in data analysis software allows users to create a menu of assay templates for instant recall with these features:
- Selectable plate formatting
- Alphanumeric test naming
- Automatic interpretation options
- Duplicate well options
- Curve plotting and editing
- Flags and error messages

The Ultimate Stellar Solution

Unlike other test platforms, ALPCO’s line of chemiluminescent assays does not require expensive high-end instrumentation. The STELLUX® ELISAs are 96-well black plate assays requiring a standard chemiluminescent (glow) reader.

The STELLUX® Chemiluminescent Plate Reader was developed as an affordable solution that only occupies a small amount of valuable laboratory bench space. The STELLUX® Chemiluminescent ELISAs and Plate Reader are ideal for use in academic institutions, contract research organizations, core reference laboratories, and pharmaceutical companies.